Variant Allele Fraction Calculation

Estimate observed VAF, confidence intervals, expected clonal VAF under purity and copy number assumptions, and a practical cancer cell fraction estimate. This calculator is designed for molecular pathology, translational research, and NGS quality review workflows.

Input Parameters

Results

Expert Guide to Variant Allele Fraction Calculation

Variant allele fraction, commonly abbreviated as VAF, is one of the most used measurements in next generation sequencing interpretation. At a basic level, it represents the fraction of sequencing reads at a locus that carry the alternate allele. In practical terms, VAF connects raw sequencing output to biological interpretation: tumor clonality, potential germline origin, minimal residual disease trends, mosaicism, and quality confidence for clinical reporting. Because modern oncology and inherited disease diagnostics increasingly rely on NGS assays, clear and accurate VAF calculation is essential for every molecular laboratory and research team.

The core formula is straightforward: VAF equals alternate reads divided by total informative reads. If 85 reads support a mutation and 315 reads support reference sequence, the total depth is 400 and the VAF is 85 divided by 400, or 21.25%. However, interpretation is not just arithmetic. The same 21% value can mean very different things depending on tumor purity, copy number status, assay error profile, and bioinformatics filtering logic. This is why a complete VAF workflow usually includes confidence intervals, context-specific thresholds, and copy number aware modeling.

Why VAF is central in molecular diagnostics

• Somatic oncology: VAF helps estimate whether a mutation is likely clonal, subclonal, or potentially due to normal contamination.
• Germline testing: Heterozygous variants often cluster around 50% VAF and homozygous variants around 100%, with assay-specific deviations.
• Mosaic disorders: VAF may be much lower than 50%, requiring higher depth and strong error suppression methods.
• Treatment monitoring: Longitudinal VAF decline or rise can reflect response, resistance, or recurrence.
• Quality control: Extremely low VAF near assay limit of detection requires technical confirmation and strict confidence logic.

Step by step calculation framework

1. Collect alternate and reference read counts after quality filters.
2. Compute total depth as ALT plus REF.
3. Calculate observed VAF = ALT / (ALT + REF).
4. Estimate uncertainty using a binomial confidence interval.
5. For tumor samples, incorporate purity and local copy number to estimate expected clonal VAF and cancer cell fraction.
6. Compare against assay validation metrics such as precision and lower limit of detection.

In high quality targeted panels, depth can exceed 500x to 1000x, enabling robust detection of low frequency variants. Yet depth alone does not guarantee accuracy. Base quality, mapping quality, strand balance, molecular barcode usage, and context-specific artifacts matter. For example, FFPE deamination can generate low level C>T artifacts that mimic true mutations. This is why VAF interpretation should be integrated with orthogonal quality features, not used as a stand alone decision metric.

Observed VAF versus biologically expected VAF

For a pure diploid sample, a heterozygous germline variant should trend near 50% VAF. In tumor tissue, reality is more complex due to non tumor cells and chromosomal changes. A simple purity and copy number aware model for a clonal single copy mutation is:

Expected clonal VAF = (purity x mutant copies) / (purity x tumor total copy number + (1 – purity) x 2)

This equation explains why even clearly clonal driver mutations may appear below 50% VAF in samples with low purity or copy number gain. Conversely, loss of the reference allele can increase observed VAF beyond typical heterozygous expectations.

Typical assay performance ranges

Assay Type	Common Mean Depth	Typical Validated LOD (SNV)	Approximate Technical CV at Low VAF
Amplicon panel without UMI	500x to 1500x	2% to 5% VAF	15% to 30% near LOD
Hybrid capture panel without UMI	300x to 800x	3% to 5% VAF	20% to 35% near LOD
UMI error corrected panel	2000x to 20000x raw	0.1% to 1% VAF	10% to 25% near LOD
Ultra deep ctDNA targeted assay	10000x+	0.01% to 0.1% in optimized workflows	Method dependent, often high near floor

The ranges above summarize values commonly reported across assay validation studies and clinical laboratory documentation. Exact performance always depends on chemistry, bioinformatics, sample quality, and variant class. Small insertions and deletions often have higher practical LOD than single nucleotide variants, and homopolymer contexts can reduce precision in some platforms.

Confidence intervals and statistical interpretation

A VAF point estimate is incomplete without uncertainty bounds. Because read counts are discrete observations, a binomial framework is usually applied. If depth is low, confidence intervals widen quickly. For instance, 5 alternate reads out of 50 total depth gives a 10% VAF, but uncertainty is much larger than 50 out of 500 depth, even though the point estimate is identical. In clinical reporting, this impacts how aggressively one should classify low frequency findings near actionability thresholds.

Laboratories often define minimum depth requirements per reportable region and may set additional site specific depth requirements for known hotspots. This prevents over interpretation of unstable VAF estimates. For longitudinal monitoring, confidence intervals also help determine whether an apparent change in VAF is likely true biological drift or expected sampling noise.

How purity, ploidy, and copy number reshape conclusions

One of the most frequent interpretation mistakes is treating VAF as equivalent to tumor cell fraction without adjustment. In mixed samples, normal cell DNA dilutes the tumor signal. Copy number events further distort observed proportions. A mutation with a 20% observed VAF in a sample with 40% purity can still be clonal if there is copy number gain at the locus. Conversely, a 40% VAF can be subclonal in a sample with high purity and loss of heterozygosity. This is why copy number integrated interpretation is now standard in many molecular tumor boards.

Scenario	Purity	Tumor CN	Mutant Copies	Expected Clonal VAF
Diploid clonal single copy mutation	100%	2	1	50.0%
Diploid clonal, moderate normal contamination	60%	2	1	30.0%
Copy number gain (CN=4), clonal single copy	70%	4	1	18.9%
Copy neutral diploid with two mutant copies	80%	2	2	80.0%
Low purity sample, diploid clonal single copy	30%	2	1	15.0%

Recommended best practices for robust VAF use

• Report both absolute read counts and VAF percentage to maintain transparency.
• Include depth and confidence interval for low frequency variants.
• Use molecular barcodes where possible for ultra low VAF applications such as ctDNA.
• Integrate site specific artifact knowledge, especially in FFPE samples.
• Interpret with copy number and purity context before assigning clonality.
• Confirm near-threshold findings with orthogonal assays when clinically necessary.
• Track longitudinal trends with consistent bioinformatics pipeline versions.

Clinical and research use cases

In solid tumors, VAF can support driver prioritization, resistance mechanism tracking, and trial eligibility assessments. In hematologic malignancies, clonal architecture often depends on comparing VAFs across multiple mutations and timepoints, corrected for local copy number and sample composition. In inherited disease diagnostics, VAF helps identify mosaic variants in parents of affected children, which can alter recurrence risk counseling. In pharmacogenomics and transplantation settings, mixed DNA populations can also produce non classical VAF distributions that require careful contextual interpretation.

No universal cutoff defines pathogenic importance. Some therapeutically actionable variants are present at low VAF but still clinically relevant, especially in resistance pathways where subclones can expand under treatment pressure. Conversely, low level variants in genes prone to clonal hematopoiesis can complicate interpretation in plasma based assays. This emphasizes multidisciplinary review with molecular pathologists, oncologists, and bioinformaticians.

Common pitfalls to avoid

1. Assuming 50% automatically means germline heterozygous without matched normal data.
2. Ignoring strand bias and read position bias in very low VAF calls.
3. Failing to account for duplicate reads or UMI family collapse behavior.
4. Using tumor only interpretation without evaluating possible clonal hematopoiesis in plasma.
5. Over interpreting very small VAF shifts that are inside expected technical variance.

Authoritative educational references

For formal definitions, assay considerations, and genomic testing context, review these sources:

• National Cancer Institute (.gov): Precision medicine and molecular profiling in cancer care
• NIH NCBI Bookshelf (.gov): Clinical overview of next generation sequencing concepts
• MedlinePlus Genetics (.gov): Sequencing fundamentals and test interpretation context

Final interpretation framework

A high quality VAF interpretation combines four layers: analytical validity, statistical confidence, biological context, and clinical relevance. Analytical validity asks whether the call is technically trustworthy at that depth and quality profile. Statistical confidence quantifies uncertainty around the observed value. Biological context translates VAF through purity and copy number dynamics. Clinical relevance finally determines whether the finding informs diagnosis, prognosis, treatment, or monitoring. When these layers are used together, VAF becomes far more than a percentage: it becomes a rigorous decision support metric for precision medicine.